🔴 Niagen Bioscience is trading 10.12% down today after Q3 sales miss and weaker ingredient outlook

Niagen Bioscience is trading at $2.23, down 10.12%, after November 4 earnings missed expectations and management tempered its outlook.

• Q3 sales were $27.2 million, down 20% year over year and below analyst expectations; net loss was $1.2 million.
• Management cited competitive ingredient-market headwinds and said the ingredient segment may finish 2026 below the prior year.
• Positive cash flow and $69.5 million in cash provided some balance, while broad-market declines added pressure.